Gufic Biosciences Limited (NSE:GUFICBIO)
India
· Delayed Price · Currency is INR 370.65
-2.15 (-0.58%)
Jun 13, 2025, 3:29 PM IST
Gufic Biosciences Revenue
In the fiscal year ending March 31, 2025, Gufic Biosciences had annual revenue of 8.20B INR with 1.63% growth. Gufic Biosciences had revenue of 2.05B in the quarter ending March 31, 2025, with 5.14% growth.
Revenue
8.20B
Revenue Growth
+1.63%
P/S Ratio
4.55
Revenue / Employee
5.50M
Employees
1,491
Market Cap
37.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 8.20B | 131.40M | 1.63% |
| Mar 31, 2024 | 8.07B | 1.16B | 16.80% |
| Mar 31, 2023 | 6.91B | -885.35M | -11.36% |
| Mar 31, 2022 | 7.79B | 2.91B | 59.76% |
| Mar 31, 2021 | 4.88B | 1.09B | 28.74% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 271.45B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 122.07B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Alkem Laboratories | 129.65B |
Gufic Biosciences News
- 4 months ago - Gufic Biosciences Ltd (BOM:509079) Q3 2025 Earnings Call Highlights: Navigating Profitability ... - GuruFocus
- 4 months ago - Q3 2025 Gufic Biosciences Ltd Earnings Call Transcript - GuruFocus